Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 10/20 | 0.42 |
| ▸ | MEN1 | O00255 | 8/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.42 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | HTT | P42858 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.38 |
| ▸ | TP53 | P04637 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1032800 | 1.00 | CYP2C19 (0.43) | CYP2C19GAAMEN1KMT2AHSD17B10 | |
| SCHEMBL28071904 | 0.85 | CYP2C19 (0.42) | CYP2C19GAAMEN1KMT2AHSD17B10 | |
| SCHEMBL5828815 | 0.85 | CYP2C19 (0.42) | CYP2C19GAAMEN1KMT2AHSD17B10 | |
| SCHEMBL7607064 | 0.82 | MME (0.48) | MMEL3MBTL1 | |
| SCHEMBL7607068 | 0.82 | MME (0.48) | MMEL3MBTL1 | |
| SCHEMBL7739887 | 0.82 | NAALAD2 (0.46) | CYP2C19GAAMEN1KMT2AHSD17B10 | |
| SCHEMBL29159326 | 0.81 | MEN1 (0.45) | GAAMEN1KMT2AHSD17B10MAPT | |
| SCHEMBL27548953 | 0.80 | MMP2 (0.42) | CYP2C19GAAMEN1KMT2AHSD17B10 | |
| SCHEMBL10670688 | 0.78 | GAA (0.47) | CYP2C19GAAMEN1KMT2AHSD17B10 | |
| SCHEMBL29126042 | 0.75 | CTSK (0.41) | CYP2C19GAAMEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301279-B1 | ADSORPTION METHOD AND LIGANDS | CYTIVA BIOPROCESS R & D AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| US-20170172957-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. | 2017-06-22 | — | — | US | disclosed |
| EP-2714029-B1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN INC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9415031-B2 | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders | ALLERGAN, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20140221453-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741955-B2 | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders | ALLERGAN, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8735451-B2 | D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20120329851-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. | 2012-12-27 | — | — | US | disclosed |
| WO-2012166533-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012166544-A1 | D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2002053288-A2 | A METHOD FOR THE MANUFACTURE OF COMPOSITIONS CONTAINING LOW CONCENTRATIONS OF SALTS | AMERSHAM BIOSCIENCES AB (SE) | 2002-07-11 | — | — | WO | disclosed |
| WO-2002013848-A1 | HIGHLY HOMOGENEOUS MOLECULAR MARKERS FOR ELECTROPHORESIS | INVITROGEN CORPORATION (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002005959-A2 | ADSORPTION METHOD AND LIGANDS | AMERSHAM BIOSCIENCES AB (SE) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001038228-A1 | A METHOD FOR ANION-EXCHANGE ADSORPTION AND THIOETHER ANION-EXCHANGERS | AMERSHAM BIOSCIENCES AB (SE) | 2001-05-31 | — | — | WO | disclosed |
| WO-2001038227-A2 | A METHOD FOR ANION-EXCHANGE ADSORPTION AND ANION-EXCHANGERS | AMERSHAM BIOSCIENCES AB (SE) | 2001-05-31 | — | — | WO | disclosed |
| EP-1003751-A1 | HYDROXAMIC ACID SUBSTITUTED FUSED HETEROCYCLIC METALLOPROTEINASE INHIBITORS | AMGEN INC. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999006410-A1 | HYDROXAMIC ACID SUBSTITUTED FUSED HETEROCYCLIC METALLOPROTEINASE INHIBITORS | AMGEN INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| US-5834460-A | FOR TREATMENT OF BRAIN OR PSYCHOLOGICAL DISORDERS, ALZHEIMER*S DISEASE, MENTAL RETARDATION OR AUTISM | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| CN-1121713-A | serine derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1996-05-01 | — | — | CN | disclosed |
| EP-0696586-A1 | SERINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-02-14 | — | — | EP | disclosed |